Bright minds biosciences comments on recent trading activity

Vancouver, british columbia, aug. 18, 2022 (globe newswire) -- bright minds biosciences (“bright minds,” “bmb” or the “company”) (nasdaq: drug) (cse: drug), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news release in response to a request by the investment industry regulatory organization of canada (“iiroc”) to comment on recent trading activity of its stock.
DRUG Ratings Summary
DRUG Quant Ranking